Effect of orlistat on cardiovascular disease risk in obese adults

Diabetes, Obesity and Metabolism

Volumn 7, Issue 3, 2005, Pages 254-262

  Swinburn, Boyd A ^a,j   Carey, D ^b,k   Hills, A P ^c   Hooper, M ^d,i   Marks, S ^e   Proietto, J ^f,l   Strauss, B J ^e   Sullivan, D ^g   Welborn, T A ^h   Caterson, I D ⁱ  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j DEAKIN UNIVERSITY   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l HEIDELBERG REPATRIATION HOSPITAL   (Australia)

more..

Author keywords

Anti obesity drugs; CVD risk factors; Obesity; Weight loss

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; AUSTRALIA; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CALCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW ZEALAND; OBESITY; PARALLEL DESIGN; PHYSICAL ACTIVITY; PREDICTION; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 20244377226     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00467.x     Document Type: Article

References (23)

1. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Geneva, World Health Organisation, 2000. WHO Technical Report Series 894.
2. Poirier P, Despres JP. Exercise in weight management of obesity. Cardiol Clin 2001; 19: 459-470.
3. Pasanisi F, Contaldo F, de Simone G, Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 2001; 11: 401-406.
4. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for-obesity. Int J Obes Relat Metab Disord 2003; 27: 591-597.
5. O'Meara SO, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1-79.
6. Leung WY, Neil Thomas G, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003; 25: 58-80.
7. Hanif MW, Kumar S. Pharmacological management of obesity. Expert Opin Pharmacother 2002; 3: 1711-1718.
8. Rissanen A, Lean M, Rossner S, Segal KR, Sjostrom L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003; 27: 103-109.
9. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002; 56: 494-499.
10. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
11. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
12. Jackson PR. The influence of absolute cardiovascular risk, patient utilities and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 2003; 21: 1631-1634.
13. National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. N Z Med J 1996; 109: 224-231.
14. Astrup A, Grunwald GK, Melanson EL, Saris WH, Hill JO. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord 2000; 24: 1545-1552.
15. Hollander P, Elbein SC, Kelley D et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288-1294.
16. Hauptman J, Lucas C, Boldrin M, Collins H, Segal K. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160-166.
17. Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
18. Rossner S, Sjostrom L, Noack R, Meinders AE, Nosedal G. Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 49-61.
19. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306-313.
20. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242.
21. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40.
22. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-1721.
23. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87: 827-831.